EB01 employs a novel mechanism of action against a common inflammation pathway. Unlike steroids and other anti-inflammatory drugs, like ibuprofen, the topical treatment being developed by Edesa is intended to inhibit the inflammatory process at its inception rather than after inflammation has occurred. In two previous clinical studies, EB01 has demonstrated significant improvement of multiple symptoms in contact dermatitis patients.
There are limited options for ACD patients and we have been pleased with the level of interest from physicians in the U.S., said Dr. Par Nijhawan, Chief Executive Officer of Edesa. The company is committed to rapidly advancing our clinical plans and remains on track to initiate our clinical study for EB01.
In addition to its lead product candidate, Dr. Nijhawan noted that the company plans to selectively target additional indications within the areas of dermatology and gastroenterology. The company also plans to expand its portfolio with assets that can drive long-term growth opportunities.
This is an active and exciting time for Edesa and we look forward to providing clinical and business updates over the coming quarter, said Dr. Nijhawan.